These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30882604)

  • 1. A pilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension.
    Azizi M; Courand PY; Denolle T; Delsart P; Zhygalina V; Amar L; Lantelme P; Mounier-Vehier C; De Mota N; Balavoine F; Llorens-Cortes C
    J Hypertens; 2019 Aug; 37(8):1722-1728. PubMed ID: 30882604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins.
    Ferdinand KC; Balavoine F; Besse B; Black HR; Desbrandes S; Dittrich HC; Nesbitt SD
    Circulation; 2019 Jul; 140(2):138-146. PubMed ID: 31014072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase a inhibitor prodrug.
    Balavoine F; Azizi M; Bergerot D; De Mota N; Patouret R; Roques BP; Llorens-Cortes C
    Clin Pharmacokinet; 2014 Apr; 53(4):385-95. PubMed ID: 24337978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of firibastat in combination with enalapril and hydrochlorothiazide on blood pressure and vasopressin release in hypertensive DOCA-salt rats.
    Marc Y; Hmazzou R; De Mota N; Balavoine F; Llorens-Cortes C
    Biomed Pharmacother; 2021 Aug; 140():111682. PubMed ID: 34020248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain ACE2 activation following brain aminopeptidase A blockade by firibastat in salt-dependent hypertension.
    Hmazzou R; Marc Y; Flahault A; Gerbier R; De Mota N; Llorens-Cortes C
    Clin Sci (Lond); 2021 Mar; 135(6):775-791. PubMed ID: 33683322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Brain Aminopeptidase A: A New Strategy for the Treatment of Hypertension and Heart Failure.
    Marc Y; Boitard SE; Balavoine F; Azizi M; Llorens-Cortes C
    Can J Cardiol; 2020 May; 36(5):721-731. PubMed ID: 32389345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Firibastat: a Novel Treatment for Hypertension.
    Nesbitt SD
    Curr Hypertens Rep; 2021 Dec; 23(12):46. PubMed ID: 34950965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats.
    Marc Y; Gao J; Balavoine F; Michaud A; Roques BP; Llorens-Cortes C
    Hypertension; 2012 Aug; 60(2):411-8. PubMed ID: 22710644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study.
    Gunawardhana L; McLean L; Punzi HA; Hunt B; Palmer RN; Whelton A; Feig DI
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29102979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NI956/QGC006, a Potent Orally Active, Brain-Penetrating Aminopeptidase A Inhibitor for Treating Hypertension.
    Keck M; De Almeida H; Compère D; Inguimbert N; Flahault A; Balavoine F; Roques B; Llorens-Cortes C
    Hypertension; 2019 Jun; 73(6):1300-1307. PubMed ID: 31067198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of four doses of tasosartan in patients with essential hypertension. Tasosartan Investigator's Group.
    Lacourcière Y; Pool JL; Svetkey L; Gradman AH; Larochelle P; de Champlain J; Smith WB
    Am J Hypertens; 1998 Apr; 11(4 Pt 1):454-61. PubMed ID: 9607384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Knowledge about the New Drug Firibastat in Arterial Hypertension.
    Hansen E; Grimm D; Wehland M
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).
    Coca A; Calvo C; García-Puig J; Gil-Extremera B; Aguilera MT; de la Sierra A; Martín-Hidalgo A; Marín R;
    Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients.
    Azizi M; Linhart A; Alexander J; Goldberg A; Menten J; Sweet C; Ménard J
    J Hypertens; 2000 Aug; 18(8):1139-47. PubMed ID: 10954007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain renin-angiotensin system blockade with orally active aminopeptidase A inhibitor prevents cardiac dysfunction after myocardial infarction in mice.
    Boitard SE; Marc Y; Keck M; Mougenot N; Agbulut O; Balavoine F; Llorens-Cortes C
    J Mol Cell Cardiol; 2019 Feb; 127():215-222. PubMed ID: 30599150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential time effect profiles of amlodipine, as compared to valsartan, revealed by ambulatory blood pressure monitoring, self blood pressure measurements and dose omission protocol.
    Radauceanu A; Boivin JM; Bernaud C; Fay R; Zannad F;
    Fundam Clin Pharmacol; 2004 Aug; 18(4):483-91. PubMed ID: 15312156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.
    Lee H; Kim KS; Chae SC; Jeong MH; Kim DS; Oh BH
    Clin Ther; 2013 Sep; 35(9):1337-49. PubMed ID: 23932463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aminopeptidase A inhibitors as centrally acting antihypertensive agents.
    Bodineau L; Frugière A; Marc Y; Claperon C; Llorens-Cortes C
    Heart Fail Rev; 2008 Sep; 13(3):311-9. PubMed ID: 18175217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K; Ogihara T; Saruta T; Kuramoto K;
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative Efficacy of the Influence of Fixed Combinations of Antihypertensive Drugs That Block the Renin-Angiotensin-Aldosterone System, With Thiazide Diuretics on the Parameters of Ambulatory Blood Pressure Monitoring].
    Ostroumova OD; Garelik IA
    Kardiologiia; 2016 Dec; 56(12):20-26. PubMed ID: 28290800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.